By exploiting synthetic lethality, PARP inhibitors (PARPi) selectively target tumors with homologous recombination deficiency (HRD) and are integral to precision therapy in ovarian, breast, and prostate cancers. This evidence concerns the gene PARP1 and hypoparathyroidism-retardation-dysmorphism syndrome.